The funding will allow 52North to move its products, including its Neutrocheck point-of-care device, toward commercialization.

Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable ...

X4 Pharmaceuticals (XFOR) announced its upcoming presentations at the 66th American Society of Hematology Annual Meeting and Exposition, ...

Raleigh: Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of ...

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity ...

Symposia Title Description Speaker Time, Location Communicating a Diagnosis of Dravet Syndrome (DS) to Parents/Caregivers: An International ...

Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized ...

Granulocyte Concentrate reduces mortality and benefits neutropenic children with severe infections suggests a study published ...

Fungal infections in patients undergoing cancer treatment present a considerable clinical hurdle due to their weakened immune ...